This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Molecular Targets for Cancer
joint with Mouse Models at the Frontiers of Cancer Discovery
Organizer(s): William G. Kaelin Jr. and Sara A. Courtneidge
Date: March 18 - 23, 2007
Location: Whistler Conference Centre, Whistler, BC, Canada
Part of the Translational Medicine Series, Sponsored by Pfizer Global Research & Development
Summary of Meeting:
The molecular circuits that are altered in cancers and responsible for malignant transformation are coming into better focus. In some cases cancer cells become ‘addicted’ to these abnormal circuits (networks). Discoveries related to cancer-relevant mutations, and the dependencies they create, will likely accelerate due to cancer resequencing efforts and phenotypic screens with genome-wide si/shRNA libraries. The success of imatinib for both chronic myelogenous leukemia and gastrointestinal stromal tumor and of gefitinib for lung cancers driven by mutant EGFR confirms that drugs targeting oncoproteins can induce tumor regressions with acceptable toxicity. Because of this, a number of agents that inhibit receptor tyrosine kinases, as well as downstream signaling molecules such as those in the Ras-Raf pathway and PI3K-AKT-mTOR pathway, are now being developed. The validity of preclinical models, and the need for robust pharmacodynamic assays, remains a challenge. This meeting will bring together experts and trainees to discuss these challenges in the context of present and future cancer drug targets.
Scholarship Deadline: November 20 2006
Discounted Abstract Deadline: November 20 2006
Abstract Deadline: December 19 2006
Discounted Registration Deadline: January 18 2007
We gratefully acknowledge additional support for this conference from:
Ariadne GenomicsCell Signaling Technology, Inc.Educational donation provided by AmgenEducational grant from Millennium Pharmaceuticals, Inc., The Takeda Oncology CompanyEntreMed, Inc.Integrated DNA TechnologiesInvitrogen CorporationPfizer Global Research & DevelopmentTeva Pharmaceutical Industries Ltd.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Pfizer Global Research & Development

Proteolix, Inc.

Wyeth Pharmaceuticals
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA124284-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found